High-mobility group box 1 (HMGB1) is increasingly recognized as a critical player in epilepsy pathogenesis and progression, as demonstrated by studies focusing on its role as a biomarker in the disease.
Patients with drug-resistant epilepsy show higher levels of blood HMGB1 compared to healthy controls or drug-resistant patients. These findings are crucial because there are no sensitive and specific biomarkers of drug-resistant epilepsy.
Other studies found that high levels of HMGB1 in epilepsy are linked to drug resistance mechanism.
HMGB1 can act as a clinical biomarker, distinguishing between drug-resistant and drug-responsive epilepsy with high specificity and selectivity.
Future researches most probably will elucidate the relationship between HMGB1 levels and epilepsy, with the potential for developing new targets and effective treatments.
HMGBiotech provides comprehensive information to facilitate informed decision-making for research involving HMGB1.
Discover our HMGB1 proteins
Read the full articles about the studies:
https://pubmed.ncbi.nlm.nih.gov/36933099/
https://pubmed.ncbi.nlm.nih.gov/34747496/
